Jim Simons Adial Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.21 - $0.37 $1,302 - $2,294	6,200 Added 6.14%	107,100 $22,000
Q1 2023 May 12, 2023	SELL	$0.24 - $0.56 $36,236 - $84,552	-150,986 Reduced 59.94%	100,900 $35,000
Q4 2022 Feb 13, 2023	BUY	$0.2 - $0.31 $21,531 - $33,373	107,656 Added 74.64%	251,886 $54,000
Q3 2022 Nov 14, 2022	SELL	$0.03 - $0.58 $755 - $14,598	-25,170 Reduced 14.86%	144,230 $50,000
Q2 2022 Aug 12, 2022	BUY	N/A	149,442 Added 748.78%	169,400 $227,000

Q1 2022 May 13, 2022	BUY	N/A	19,958 New	19,958 $40,000
Q1 2021 May 13, 2021	SELL	N/A	-98,900 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	N/A	5,993 Added 6.45%	98,900 $168,000
Q3 2020 Nov 13, 2020	BUY	N/A	50,900 Added 121.17%	92,907 $207,000
Q2 2020 Aug 13, 2020	BUY	N/A	42,007 New	42,007 $58,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $28.2M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.